Korro Bio, Inc. (KRRO)
(Delayed Data from NSDQ)
$36.36 USD
+0.39 (1.08%)
Updated Aug 13, 2024 04:00 PM ET
After-Market: $36.15 -0.21 (-0.58%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Korro Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 166 | 83 | 131 | 220 | 217 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 4 | 4 | 5 | 4 |
Total Current Assets | 173 | 87 | 135 | 225 | 221 |
Net Property & Equipment | 16 | 3 | 6 | 7 | 2 |
Investments & Advances | 0 | 0 | 12 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 6 | 2 | 2 | 2 | 0 |
Total Assets | 222 | 121 | 185 | 265 | 223 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 3 | 3 | 6 | 1 |
Current Portion Long-Term Debt | 0 | 10 | 1 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 6 | 6 | 7 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 14 | 48 |
Total Current Liabilities | 19 | 21 | 11 | 27 | 53 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 4 | 14 | 15 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 52 | 52 | 55 | 72 | 56 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 353 | 331 | 311 | 288 | 236 |
Retained Earnings | -183 | -262 | -180 | -95 | -69 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 170 | 69 | 131 | 192 | 167 |
Total Liabilities & Shareholder's Equity | 222 | 121 | 185 | 265 | 223 |
Total Common Equity | 170 | 69 | 131 | 192 | 167 |
Shares Outstanding | 8.00 | 0.70 | 0.60 | 0.60 | 0.60 |
Book Value Per Share | 21.24 | 98.86 | 218.03 | 320.82 | 278.93 |
Fiscal Year End for Korro Bio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 139 | 166 | 42 | 46 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 7 | 1 | 2 |
Total Current Assets | NA | 146 | 173 | 43 | 48 |
Net Property & Equipment | NA | 21 | 16 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 6 | 6 | 2 | 2 |
Total Assets | NA | 198 | 222 | 46 | 79 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 7 | 0 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 5 | 10 | 8 | 5 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 11 | 19 | 10 | 8 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 47 | 52 | 10 | 34 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 354 | 353 | 340 | 337 |
Retained Earnings | NA | -203 | -183 | -304 | -292 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 151 | 170 | 37 | 45 |
Total Liabilities & Shareholder's Equity | NA | 198 | 222 | 46 | 79 |
Total Common Equity | 0 | 151 | 170 | 37 | 45 |
Shares Outstanding | 9.20 | 8.00 | 8.00 | 0.70 | 0.70 |
Book Value Per Share | 0.00 | 18.92 | 21.24 | 52.49 | 64.87 |